Krufton (Nilotinib)

Nilotinib binds to the ATP‑binding pocket of the BCR‑ABL fusion protein, locking it in an inactive state. This blocks downstream signaling pathways that promote cell proliferation and survival, leading to reduced growth of leukemic cells and, ultimately, their death.

The dosage of Krufton is individualized by the prescribing physician based on the patient’s clinical condition, response, and tolerance. The prescriber determines the appropriate strength, frequency, and duration of therapy according to current medical guidelines.

Safety data for nilotinib in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit justifies the risk, and breastfeeding is not recommended while on therapy because the drug may be excreted in milk.

To request Krufton, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with first‑generation inhibitors such as imatinib, nilotinib (Krufton) offers higher potency against BCR‑ABL and can be effective in patients who have resistance or intolerance to imatinib. However, it may have a different safety profile, including a higher risk of cardiovascular events, requiring careful monitoring.

Krufton tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from moisture and direct sunlight. Do not refrigerate or freeze the product, and keep it out of reach of children.

Krufton is taken orally, usually as a tablet, with a moderate‑fat meal to improve absorption. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider, without crushing or chewing the tablet.

The most serious risks include QT interval prolongation leading to potentially fatal arrhythmias, arterial occlusive events such as peripheral vascular disease, severe pancreatitis, and significant hepatic injury. Prompt medical attention is required if symptoms such as chest pain, shortness of breath, severe abdominal pain, or jaundice occur.

Krufton should be avoided in patients with a known hypersensitivity to nilotinib or any component of the formulation, in those with a history of prolonged QT interval, uncontrolled cardiovascular disease, or severe hepatic impairment. It is also contraindicated in patients taking strong CYP3A4 inhibitors without appropriate dose adjustment.